Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cystic Fibrosis, Rhinosinusitis or Lung Diseases
and you are
over 7
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Patients with cystic fibrosis frequently develop chronic rhinosinusitis. Bacterial colonization is facilitated by a reduced mucociliary function and some previous studies suggest that the microbiology of the upper airways might influence the microbiology of the lower airway. The aim of this randomized control study is to demonstrate efficacy of antibiotic delivered by nebulized sonic aerosol therapy to decrease the bacterial load in sinuses and medium ostia and to improve the sino-nasal symptoms and endoscopic scores, quality of life and lung function

Provided treatments

  • Drug: Tobramycin nebulized nasally
  • Drug: Physiologic serum nebulized nasally
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02888730. The sponsor of the trial is Virginie ESCABASSE and it is looking for 86 volunteers for the current phase.
Official trial title:
Efficacy of Antibiotic (Tobramycin) Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients: A Multicenter Double-blind Randomized Controlled Trial